The significance of heavy/light chain immunoglobulin pairs (Hevylite™) in multiple myeloma
Authors:
V. Ščudla 1; T. Pika 2; J. Minařík 2
Authors‘ workplace:
3. interní klinika-NRE Lékařské fakulty Univerzity Palackého a Fakultní nemocnice, Olomouc
1; Hemato-onkologická klinika Fakultní nemocnice, Olomouc
2
Published in:
Transfuze Hematol. dnes,20, 2014, No. 4, p. 107-116.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
This article aims to provide information regarding the benefits of the new, highly sensitive analytical method for serum immunoglobulins (HevyliteTM). The assay allows separate quantitative analysis of heavy/light chain immunoglobulin pairs (HLC), i.e. monoclonal („involved“) and polyclonal („uninvolved“) pairs, including their mutual ratio (HLC-r) in multiple myeloma. The article compares in depth the benefits of HevyliteTM versus standard techniques in the diagnosis and monitoring of multiple myeloma course; the evaluation of response to treatment, including minimal residual disease; the early detection of relapse and the prognostic stratification in terms of response duration and overall survival.
Key words:
multiple myeloma, monoclonal immunoglobulin heavy/light chain pairs, HevyliteTM, diagnosis, stratification, minimal residual disease, prognosis
Sources
1. International Myeloma Working Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International myeloma working group. Brit J Haematol 2003; 121: 749-757.
2. Hájek R, Adam Z, Ščudla V, et al. Souhrn doporučení CMG 2012 „Diagnostika a léčba mnohočetného myelomu“. Transfuze Hematol dnes 2012; Suppl. 1 118: 5-89.
3. Vávrová J. Stanovení volných lehkých řetězců a HevyliteTM u monoklonálních gamapatií. In: Maisnar V, Tichý M, et al. Monoklonální imunoglobuliny – výskyt, význam a možnosti jejich průkazu. 1. vyd. Praha: Nucleus Hradec Králové 2012: 55-60. ISBN: 978-80-87009-97-1.
4. Bradwell AR. Analysis of immunoglobulin heavy chain/light chain pairs (HevyliteTM ). In: Bradwell AR. Serum free light chain analysis (plus Hevylite). 6th edit, Birmingham: The Binding Site Ltd 2010: 301 till 320. ISBN: 9780704427969.
5. Bradwell AR, Harding SJ, Fourrier NJ, et al. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chemistry 2009; 55: 1646-1655.
6. Ludwig H, Milosavljevic D, Zojer N, et al. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia 2013; 27: 213-219.
7. Ščudla V, Pika T, Heřmanová Z. Hevylite – nová analytická metoda v diagnostice a hodnocení průběhu monoklonálních gamapatií. Klin Biochem Metab 2010; 18: 62-68.
8. Bradwell A, Harding S, Fourrier N, et al. Prognostic utility of intact immunoglobulin Ig´kappa/Ig´lambda ratios in multiple myeloma patients. Leukemia 2013; 27: 202-207.
9. Keren DF. Heavy/light-chain analysis of monoclonal gammopathies. Clin Chemistry 2009; 55: 1606-1608.
10. Wang H, Gao C, Xu L, et al. Laboratory characterisations on 2007 cases of monoclonal gammopathies in East China. Cell Mol Immunol 2008; 5: 293-298.
11. Avet-Loiseau H, Harousseau JL, Moreau P, et al. Heavy/light chain specific immunoglobulin ratios at presentation are prognostic for progression free survival in the IFM 2005-01 Myeloma trial. Blood 2009; 114: 1818.
12. Wolff F, Debaugnies F, Rozen L, et al. Assessment of the diagnostic performance of IgA heavy and light chain pairs in patiens with IgA monoclonal gammopathy. Clin Biochemistry 2013; 46: 79-84.
13. Katzmann JA, Kyle RA, Benson J, et al. Screening panels for detection of monoclonal gammopathies. Clin Chemistry 2009; 55: 1517-1522.
14. Murray DL, Ryu E, Snyder MR, et al. Quantification of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clin Chemistry 2009; 55: 1523-1529.
15. Lakomy D, Lemaire-Ewing S, Denimal D, et al. Evaluation of the new HevyliteTM IgA assay for the diagnosis and follow-up of monoclonal gammopathies. Ann Biol Clin 2013; 71: 157-163.
16. Legg A, Harding S, Hughes RG, et al. Serum free light chain and Hevylite analysis in the diagnosis, monitoring and prognosis of B cell disorders. Klin Biochem Metab 2010; 18: 56-61.
17. Avet-Loiseau H, Mirbahai L, Mathiot C, et al. Nephelometric assays Ig´kappa and Ig´lambda used for diagnosing and monitoring multiple myeloma. Haematologica 2011; 96: 393.
18. Koulieris E, Panayiotidis P, Harding SJ, et al. Ratio of involved/unilvolved immunoglobulin quantification by HevyliteTM assay: clinical and prognostic impact in multiple myeloma. Exp Hematol Oncol 2012; 1: 9. http://www.enhoonline.org/content/1/1/9
19. Pika T, Heřmanová Z, Lochman P, et al. Systém HevyLiteTM u IgA monoklonálních gamapatií – první zkušenosti. Klin Biochem Metab 2011; 19: 86-91.
20. Wechalekar A, Harding S, Lachmann H, et al. Serum immunoglobulin heavy/light chain ratios (Hevylite) in patients with systemic AL amyloidosis. Amyloid 2010; 17: 186.
21. Leleu X, Koulieris E, Maltezas D, et al. Novel M-component based biomarkers in Waldenström´s macroglobulinemia. Clin Lymphoma, Myeloma Leukemia 2011; 11: 164-167.
22. Alexanian R. Blood volume in monoclonal gammopathy. Blood 1997; 49:301-307.
23. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969; 13: 1-110.
24. Salmon S, Smith B. Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest 1970; 49: 1114-1121.
25. Anderson C, Chandbury C, Kim J, et al.: Perspective-FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 2006; 27: 343-348.
26. Wines BD, Hogarth PM. IgA receptors in health and disease. Tissue Antigens 2006; 68: 103-114.
27. Chandhury C, Brooks C, Carter D, et al. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry 2006;45: 4983-4990.
28. Ščudla V, Lochman P, Pika T, et al. Analýza vztahu sérových hladin párů těžkých/lehkých řetězců imunoglobulinu (HevyliteTM) k výsledkům standardní gelové elektroforézy a nefelometrického vyšetření bílkovin séra při diagnóze mnohočetného myelomu. Čas Lék Čes 2014; (v tisku).
29. Mirbahai L, Young P, Harding S, et al. Serum free light chain (FLC) and heavy/light chain (HLC) assays provide sensitive quantitative methods for monitoring IgA multiple myeloma patients. Haematologica 2012; 97: 604.
30. Harding S, Drayson M, Lachmann H, et al. Novel nephelometric immunoassays for the sensitive detection on of IgA monoclonal gammopathies in multiple myeloma and AL amyloidosis. Haematologica 2008; 93: 668.
31. Drayson M, Berlanga O, Plant T, et al. Immunoglobulin heavy/light chain measurements during monitoring provide prognostic information of relapse after therapy in multiple myeloma patients. Blood 2012; 120: 3964a.
32. Lakomy D, Lemaire-Ewing S, Lafon I, et al. IgA heavy/light chain analysis-a new marker for the diagnosis and monitoring of myeloma patients. Haematologica 2012; 97: 590.
33. Katzmann JA, Rajkumar SV. A windows into immunoglobulin quantitation and plasma cell disease: antigen epitopes defined by the junction of immunoglobulin heavy and light chains. Leukemia 2013; 27: 1-2.
34. Tovar N, Fernandez de Larrea C, Elena M, et al. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1076-107.
35. Bhutani M, Landgren O, Korde N. Serum heavy-light chains (HLC) and free light chains (FLC) as predictors for early CR in newly diagnosed myeloma patients treated with carfilzomib, lenalidomide and dexamethasone (CRd). Blood 2013; 122: 762a.
36. Fernández de Larrea C, Tovar N, Cibeira MT, et al. Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction therapy: association with the use of novel agents. Haematologica 2011; 96: 171-173.
37. Leibson PJ, Loken MR, Panem S, et al. Clonal evolution of myeloma cells leeds to quantitative changes in immunoglobulin secretion and surface antigen expression. Proc Natl Acad Sci ISA 1979; 76: 2937-2941.
38. Murillo-Florez I, Andrade-Campos M, Montes-Limon A, et al. Predictive value of light and heavy chain analysis in multiple myeloma patients treated with bortezomib. Haematologica 2013; 98: 1519a.
39. Ludwig H, Milosavljevic D, Zojer N, et al. Supression of the non-involved HLC pair correlates with survival in newly diagnosed and relapsed/refraktory patients with myeloma. Haematologica 2014; 99(S1): P 980.
40. Matsue K, Sugihara H, Nishida Y, Yamakura M, et al. Heterogeneity of IMWG defined response assessed by FLC assay, multicolor flow cytometry, and heavy/light analysis. Clin Lymphoma Myeloma Leukemia 2013; 13: 203.
41. Avet-Louisiau H, Mirbahai L, Harousseau JL, et al. Serum immunoglobulin heavy/light chain ratios are independent risk factors for predict progression free survival in multiple myeloma. Haematologica 2010; 95: 953.
42. Donato LJ, Zeldenrust SR, Murray DL, et al. A 71-year-old woman with multiple myeloma status after stem cell transplantation. Clin Chemistry 2011; 57: 1645-1649.
43. Olivero B, Robillard N, Wuilleme S, et al. Heavy/light chain assay, potential new tool in minimal residual disease assessment. A biological study from IFM 2008 trial. Haematologica 2011; 96: 79.
44. Kraj M, Kruk B, Poglod R, et al. Evaluation of IgG, IgA and IgM monoclonal and biclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios – Hevylite assay versus immunofixation. Acta Haematologica Polonica 2011; 42: 257-271.
45. Koulieris E, Maltezas D, Eytychia N, et al. Impact of novel M-component based biomarkers on to progression free survival after treatment in intact immunoglobulin multiple myeloma. Blood 2012; 120: 21.
46. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007: 137: 240-243.
47. Dispenzieri A, Zhang L, Katzmann JA, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008;111: 4908-4915.
48. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23: 3412-3420.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2014 Issue 4
Most read in this issue
- Activity of Blood Transfusion Service in the Czech Republic 1989–2013
- The significance of heavy/light chain immunoglobulin pairs (Hevylite™) in multiple myeloma
- Retransfusion system with integrated double filtration – parameters of product quality
- Pharmacokinetics as a tool for optimising the treatment of patients with haemophilia